2022 Biomedical Pitch Competition — Final Contest
Six finalist teams emerged from over 50 participating projects to compete for the top three positions. The judging panel included multiple well-known venture capitalists.
Live event: Eastern Time 4/22 evening / Beijing Time 4/23 morning. Welcome to attend.
Register here: http://bcicglobal.mikecrm.com/q2aFtyc
Finalist Project Introductions
Paracyte Bio
Paracyte Bio is a biotechnology company founded by Dr. James DiCarlo. Paracyte Bio aims to develop new compounds and strategies to treat autoimmune diseases through parasite immunomodulatory compounds. They generate intelligent libraries of potentially immune-interactive parasitic proteins, and use high-throughput screening to identify novel immunomodulators.
Amytrx Therapeutics
Amytrx is a biotechnology company founded by Dr. Hawiger, distinguished medical professor and Louise B. McGavock Chair at VU. Amytrx completed its second financing round at a pre-money valuation of $36 million. Its product AMTX-100 is a fully human 28-amino-acid peptide for the treatment of immune-mediated diseases. The product has successfully completed Phase I/IIa for atopic dermatitis and has received FDA clearance to enter Phase IIb.
Aikili Biosystems
Aikili is a seed-stage medical diagnostics (precision oncology) company founded by Dr. Hannah Peterson (Massachusetts General Hospital) and Laura Kelley, MBA, MPH (Harvard Business School). Aikili enables near-real-time, longitudinal analysis of the tumor microenvironment by quantifying the types and abundance of cancer and immune cells from minimally invasive needle-aspirate samples of fewer than 1,000 cells. Aikili's technology is built on novel bio-orthogonal chemistry, with exclusive rights from Massachusetts General Hospital.
ARIZ Precision Medicine
ARIZ Precision Medicine is a pre-Series A biotech company founded by Brad Niles (CEO), who has more than 20 years of cancer research experience and has spent the last five years on product development. ARIZ Precision Medicine is developing potential therapeutics targeting the PRDM family of epigenetic regulators — specifically targeting genes and proteins responsible for cancer initiation, while sparing healthy cells.
Biostage
Biostage is a clinical-stage biotechnology company that uses a patient's own stem cells, grown on a porous plastic tubular scaffold, to regenerate the esophagus after surgical removal due to cancer, trauma, or birth defects. It was founded by David Green, Chairman and Director of the Harvard Business School Healthcare Industry Alumni Association. He co-founded Harvard Bioscience in 1996 and took HBIO public in 2000. In 2008 he founded Biostage (then called Harvard Apparatus Regenerative Technology) as a subsidiary of HBIO, and in 2013 led Biostage's spin-off from HBIO.
Jizhi Analytics
Jizhi Analytics aims to disrupt the medical big-data field by providing a cloud-based platform purpose-built for medical data analysis, integrating all functions into a unified one-click solution. The team includes experienced medical data researchers and AI talents as co-founders, alongside marketing experts with deep sales networks. Starting from data-analysis tools, they pursue long-term, high-level integration across medical practice, clinical research, and product-driven business.